{"id":408373,"date":"2021-01-05T08:03:29","date_gmt":"2021-01-05T13:03:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408373"},"modified":"2021-01-05T08:03:29","modified_gmt":"2021-01-05T13:03:29","slug":"outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","title":{"rendered":"Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MONMOUTH JUNCTION, N.J., Jan.  05, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Izx31um8gN6dSbGCXWO0cFBBGETGu9THqFZGdOd1e93SCiSJ0khcfD9o-fXdSZgea1Jiic2Oub5gah542gEKO6Vm9fWn8c6W-SgVm8h601M=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Outlook Therapeutics, Inc.<\/a> (Nasdaq: OTLK), a\u202flate clinical-stage\u202fbiopharmaceutical company\u202fworking to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg\u202ffor use in retinal\u202findications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will present in a fireside chat at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sF-xA85AN6t69so81OxoZqKSEJDZf5Jg8e4nkKJXIvalYn6OXj2-yiM8G6Pm7LKAtXhxJqfujBBU-3FipPBpm4MdZblIQi2C5SjcYmLei7BfyWC967d_6zB0KhWYNOqUD-YCJLTvgMIzDDZ2xl4CYA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">H.C. Wainwright BioConnect 2021 Virtual Conference<\/a> taking place January 11-14, 2021.<\/p>\n<p align=\"justify\">A <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GPgzNkDObX69PVjG1wr01TEZt0t9QZCoBDWNG-2jFGhTee2yrpE5jSIVcKC_sBlwPbU4zfy50Ym1v4knTa2_cLjmlN0-kwTkeaCuBJ6ZEy_dBfMKcHG1hh5zz6JQhpPxG0mXTFSTQfAvzn_kX-dIjw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">video webcast<\/a> of the fireside chat will be available for viewing on-demand beginning Monday, January 11, 2021, at 6:00 AM ET for those registered for the event and accessible on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HTqldgk6zmVVDpcpus6kedG8p6oEBx2Hs4up1NBRmvaHKJnr3dFjLAswfZuNnDDR3rbT_PHveJiDvUVKzI0fmFr8mccp53kO6ayxg247HzlJVNb_TlzUZIZZwwLKIHlx\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Events<\/a> page of the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5uo7GlXiZjnLCjDxLxSWgBlZfv7w5IsjCTrMii9vZ071IrRN80t2i2QWxkhj0ESrlDE-gwBK8eWBNQ_2_HdIabn9D8cHRLyNU81G0Zv8kkQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Investors<\/a> section of the Outlook Therapeutics website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PErLhtO_aMu8yaRi59YFyTxRh-59_U0HZWEHq3sax-nrOKRBlv-3NF_rqxd3FkU3U4rRtkEAXXzKa-VxkSXeYIDZYuGrrfjmFC5As-VvWhs=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">outlooktherapeutics.com<\/a>.<\/p>\n<p align=\"justify\">For more information about the event, please visit the conference website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vsW-F61BJE2nTXqzYwTL50KxM_XJ5TcREWVEHdpNzpKJK_gtpIwxpG9XZjG4xx4BM1aHWOtH9r68B95Br-JE-A==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Outlook Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010\/LYTENAVA\u2122 (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kmOY4rEDNHkz0rW9e3RA1bJVGzciF-5KygzK3Rihl4kgWUiOdBvYq3NUbb71V-MPf2_TZzUoRAn3siOXG61825sQmgGKsXUXKJdQzMpdegVhKOmBLTH0s-HmvHEWVegx\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.outlooktherapeutics.com<\/a>. <\/p>\n<p align=\"justify\">\n        <strong>CONTACTS:<\/strong><br \/>\n        \n      <\/p>\n<p>\n        <strong>Media Inquiries:<\/strong>\n      <\/p>\n<p>Harriet Ullman<br \/>Assistant Vice President<br \/>LaVoieHealthScience<br \/>T: 617-669-3082<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UvRzxTIaFAMoAAsfJfBUmo0bDqzMoX4qrOf4hmgHvRVlTtGuBBdw4L1neanEYujybr1S8Q59W-0mCZOJiZap6BltoO3t5Pa53obX-YO-3_6IaA04V3bMFAoIiKHuKN_g\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">hullman@lavoiehealthscience.com<\/a><\/p>\n<p>\n        <strong>Investor Inquiries: <\/strong>\n      <\/p>\n<p>Jenene Thomas<br \/>Chief Executive Officer<br \/>JTC Team, LLC<br \/>T: 833.475.8247<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ojR8eBruy20s_zQESiBAPwaqNekRE4UBbV3egCxPwI6E0XYBZbstJ_EO6ZrzyIHThgmoeYD8B5bTbMHcnqXG8w==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">OTLK@jtcir.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQyMSMzOTA0MjQyIzIwMjg4MjI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/841b42a0-77b4-4d5f-864b-99369e5a94c0\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MONMOUTH JUNCTION, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a\u202flate clinical-stage\u202fbiopharmaceutical company\u202fworking to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg\u202ffor use in retinal\u202findications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will present in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021. A video webcast of the fireside chat will be available for viewing on-demand beginning Monday, January 11, 2021, at 6:00 AM ET for those registered for the event and accessible on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com. For more information about the event, please visit the conference website here. About Outlook Therapeutics, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408373","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MONMOUTH JUNCTION, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a\u202flate clinical-stage\u202fbiopharmaceutical company\u202fworking to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg\u202ffor use in retinal\u202findications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will present in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021. A video webcast of the fireside chat will be available for viewing on-demand beginning Monday, January 11, 2021, at 6:00 AM ET for those registered for the event and accessible on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com. For more information about the event, please visit the conference website here. About Outlook Therapeutics, &hellip; Continue reading &quot;Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T13:03:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQyMSMzOTA0MjQyIzIwMjg4MjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference\",\"datePublished\":\"2021-01-05T13:03:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\"},\"wordCount\":264,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDQyMSMzOTA0MjQyIzIwMjg4MjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\",\"name\":\"Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDQyMSMzOTA0MjQyIzIwMjg4MjI=\",\"datePublished\":\"2021-01-05T13:03:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDQyMSMzOTA0MjQyIzIwMjg4MjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDQyMSMzOTA0MjQyIzIwMjg4MjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference - Market Newsdesk","og_description":"MONMOUTH JUNCTION, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Outlook Therapeutics, Inc. (Nasdaq: OTLK), a\u202flate clinical-stage\u202fbiopharmaceutical company\u202fworking to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg\u202ffor use in retinal\u202findications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will present in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021. A video webcast of the fireside chat will be available for viewing on-demand beginning Monday, January 11, 2021, at 6:00 AM ET for those registered for the event and accessible on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com. For more information about the event, please visit the conference website here. About Outlook Therapeutics, &hellip; Continue reading \"Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T13:03:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQyMSMzOTA0MjQyIzIwMjg4MjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference","datePublished":"2021-01-05T13:03:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/"},"wordCount":264,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQyMSMzOTA0MjQyIzIwMjg4MjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","name":"Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQyMSMzOTA0MjQyIzIwMjg4MjI=","datePublished":"2021-01-05T13:03:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQyMSMzOTA0MjQyIzIwMjg4MjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQyMSMzOTA0MjQyIzIwMjg4MjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/outlook-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408373"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408373\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}